DANCAN Stock Overview
A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.041 |
| 52 Week High | DKK 0.32 |
| 52 Week Low | DKK 0.01 |
| Beta | 2.19 |
| 11 Month Change | -24.91% |
| 3 Month Change | -46.19% |
| 1 Year Change | -84.81% |
| 33 Year Change | -98.97% |
| 5 Year Change | n/a |
| Change since IPO | -98.75% |
Recent News & Updates
Recent updates
Shareholder Returns
| DANCAN | SE Pharmaceuticals | SE Market | |
|---|---|---|---|
| 7D | -10.5% | 1.1% | -0.4% |
| 1Y | -84.8% | 91.9% | 12.9% |
Return vs Industry: DANCAN underperformed the Swedish Pharmaceuticals industry which returned 92.5% over the past year.
Return vs Market: DANCAN underperformed the Swedish Market which returned 12.9% over the past year.
Price Volatility
| DANCAN volatility | |
|---|---|
| DANCAN Average Weekly Movement | 34.8% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in SE Market | 12.3% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: DANCAN's share price has been volatile over the past 3 months.
Volatility Over Time: DANCAN's weekly volatility (35%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 12 | Jeppe Rasmussen | www.dancann.com |
DanCann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas. It sources, develops, and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. The company’s development pipeline includes EXT02 CannGros, EXT03 CannGros, EXT04 CannGros, FLS04 CannGros, and FLS05 CannGros.
DanCann Pharma A/S Fundamentals Summary
| DANCAN fundamental statistics | |
|---|---|
| Market cap | DKK 6.83m |
| Earnings (TTM) | -DKK 61.33m |
| Revenue (TTM) | DKK 6.83m |
1.0x
P/S Ratio-0.1x
P/E RatioIs DANCAN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DANCAN income statement (TTM) | |
|---|---|
| Revenue | DKK 6.83m |
| Cost of Revenue | DKK 9.82m |
| Gross Profit | -DKK 2.99m |
| Other Expenses | DKK 58.34m |
| Earnings | -DKK 61.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.37 |
| Gross Margin | -43.71% |
| Net Profit Margin | -897.54% |
| Debt/Equity Ratio | 0% |
How did DANCAN perform over the long term?
See historical performance and comparison